Newsletter

068270 - Celltrion, Inc.

068270 Summary

Biopharma

Stock Price & Overview

₩186,300 -1,800 (-0.96%) Close · Sep 7, 2026 KST

KOSPI | ₩KRW | Close: ₩186,300 ≈ US$133 · Market cap ₩43.3tn (≈ $31.0bn)

Home › 068270 › Filings

Material matter affecting investment judgment

DART

Celltrion, Inc.

Filed Sep 7, 2026 KST · Filing · receipt 20260907800002

kstock has not written this one up. The title above is a translation of the Korean form name; the filing itself is on DART, in Korean.

Read the original on DART ↗ Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory Service — the filing equivalent of EDGAR.

Korean form name: 투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 변경신청 승인)

068270

Price: ₩186,300
Change: -0.96%
Market cap: ₩43.3tn
Prev. close: ₩188,100

068270 Summary Compare to Peers

068270 data on kstock

Financials: 11 fiscal years
Valuation: Daily P/E, P/S, P/B, P/CF
Earnings: Eight quarters
Dividends: Per-share history

Every figure is taken from Celltrion, Inc.'s own DART filings and matched on IFRS account codes, so a line holds across years where the Korean wording changed.